Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans

Michael M. Swarbrick, Peter J Havel

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Adiponectin is an adipocyte hormone that links visceral adiposity with insulin resistance and atherosclerosis. It is unique among adipocyte-derived hormones in that its circulating concentrations are inversely proportional to adiposity, and low adiponectin concentrations predict the development of type 2 diabetes and cardiovascular disease. Consequently, in the decade since its discovery, adiponectin has generated immense interest as a potential therapeutic target for the metabolic syndrome and diabetes. This review summarizes current research regarding the regulation of circulating adiponectin concentrations by physiological, pharmacological, and nutritional factors, with an emphasis on human studies. In humans, plasma adiponectin concentrations are influenced by age and gender, and are inversely proportional to visceral adiposity. In vitro studies suggest that adiponectin production may be determined primarily by adipocyte size and insulin sensitivity, with larger, insulin-resistant adipocytes producing less adiponectin. While adiponectin concentrations are unchanged after meal ingestion, they are increased by significant weight loss, such as after bariatric surgery. In addition, adiponectin production is inhibited by a number of hormones, including testosterone, prolactin, glucocorticoids and growth hormone, and by inflammation and oxidative stress in adipose tissue. Smoking decreases, while moderate alcohol consumption increases, circulating adiponectin concentrations. Dietary fatty acid composition in rodents influences adiponectin production via ligand-activated nuclear receptors (PPARs); however, current evidence in humans is equivocal. In addition to PPAR agonists (such as thiazolidinediones and fibrates), a number of pharmacological agents (angiotensin receptor type 1 blockers, ACE inhibitors, and cannabinoid receptor antagonists) used in treatment of the metabolic syndrome also increase adiponectin concentrations in humans.

Original languageEnglish (US)
Pages (from-to)87-102
Number of pages16
JournalMetabolic Syndrome and Related Disorders
Volume6
Issue number2
DOIs
StatePublished - Jun 1 2008

Fingerprint

Adiponectin
Pharmacology
Adipocytes
Adiposity
Peroxisome Proliferator-Activated Receptors
Hormones
Insulin Resistance
Cannabinoid Receptor Antagonists
Angiotensin II Type 1 Receptor Blockers
Fibric Acids
Thiazolidinediones
Bariatric Surgery
Cytoplasmic and Nuclear Receptors
Angiotensin-Converting Enzyme Inhibitors
Alcohol Drinking
Prolactin
Type 2 Diabetes Mellitus
Glucocorticoids
Growth Hormone
Meals

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. / Swarbrick, Michael M.; Havel, Peter J.

In: Metabolic Syndrome and Related Disorders, Vol. 6, No. 2, 01.06.2008, p. 87-102.

Research output: Contribution to journalArticle

@article{6b64be282f7846d3a30e82a2918a969e,
title = "Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans",
abstract = "Adiponectin is an adipocyte hormone that links visceral adiposity with insulin resistance and atherosclerosis. It is unique among adipocyte-derived hormones in that its circulating concentrations are inversely proportional to adiposity, and low adiponectin concentrations predict the development of type 2 diabetes and cardiovascular disease. Consequently, in the decade since its discovery, adiponectin has generated immense interest as a potential therapeutic target for the metabolic syndrome and diabetes. This review summarizes current research regarding the regulation of circulating adiponectin concentrations by physiological, pharmacological, and nutritional factors, with an emphasis on human studies. In humans, plasma adiponectin concentrations are influenced by age and gender, and are inversely proportional to visceral adiposity. In vitro studies suggest that adiponectin production may be determined primarily by adipocyte size and insulin sensitivity, with larger, insulin-resistant adipocytes producing less adiponectin. While adiponectin concentrations are unchanged after meal ingestion, they are increased by significant weight loss, such as after bariatric surgery. In addition, adiponectin production is inhibited by a number of hormones, including testosterone, prolactin, glucocorticoids and growth hormone, and by inflammation and oxidative stress in adipose tissue. Smoking decreases, while moderate alcohol consumption increases, circulating adiponectin concentrations. Dietary fatty acid composition in rodents influences adiponectin production via ligand-activated nuclear receptors (PPARs); however, current evidence in humans is equivocal. In addition to PPAR agonists (such as thiazolidinediones and fibrates), a number of pharmacological agents (angiotensin receptor type 1 blockers, ACE inhibitors, and cannabinoid receptor antagonists) used in treatment of the metabolic syndrome also increase adiponectin concentrations in humans.",
author = "Swarbrick, {Michael M.} and Havel, {Peter J}",
year = "2008",
month = "6",
day = "1",
doi = "10.1089/met.2007.0029",
language = "English (US)",
volume = "6",
pages = "87--102",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans

AU - Swarbrick, Michael M.

AU - Havel, Peter J

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Adiponectin is an adipocyte hormone that links visceral adiposity with insulin resistance and atherosclerosis. It is unique among adipocyte-derived hormones in that its circulating concentrations are inversely proportional to adiposity, and low adiponectin concentrations predict the development of type 2 diabetes and cardiovascular disease. Consequently, in the decade since its discovery, adiponectin has generated immense interest as a potential therapeutic target for the metabolic syndrome and diabetes. This review summarizes current research regarding the regulation of circulating adiponectin concentrations by physiological, pharmacological, and nutritional factors, with an emphasis on human studies. In humans, plasma adiponectin concentrations are influenced by age and gender, and are inversely proportional to visceral adiposity. In vitro studies suggest that adiponectin production may be determined primarily by adipocyte size and insulin sensitivity, with larger, insulin-resistant adipocytes producing less adiponectin. While adiponectin concentrations are unchanged after meal ingestion, they are increased by significant weight loss, such as after bariatric surgery. In addition, adiponectin production is inhibited by a number of hormones, including testosterone, prolactin, glucocorticoids and growth hormone, and by inflammation and oxidative stress in adipose tissue. Smoking decreases, while moderate alcohol consumption increases, circulating adiponectin concentrations. Dietary fatty acid composition in rodents influences adiponectin production via ligand-activated nuclear receptors (PPARs); however, current evidence in humans is equivocal. In addition to PPAR agonists (such as thiazolidinediones and fibrates), a number of pharmacological agents (angiotensin receptor type 1 blockers, ACE inhibitors, and cannabinoid receptor antagonists) used in treatment of the metabolic syndrome also increase adiponectin concentrations in humans.

AB - Adiponectin is an adipocyte hormone that links visceral adiposity with insulin resistance and atherosclerosis. It is unique among adipocyte-derived hormones in that its circulating concentrations are inversely proportional to adiposity, and low adiponectin concentrations predict the development of type 2 diabetes and cardiovascular disease. Consequently, in the decade since its discovery, adiponectin has generated immense interest as a potential therapeutic target for the metabolic syndrome and diabetes. This review summarizes current research regarding the regulation of circulating adiponectin concentrations by physiological, pharmacological, and nutritional factors, with an emphasis on human studies. In humans, plasma adiponectin concentrations are influenced by age and gender, and are inversely proportional to visceral adiposity. In vitro studies suggest that adiponectin production may be determined primarily by adipocyte size and insulin sensitivity, with larger, insulin-resistant adipocytes producing less adiponectin. While adiponectin concentrations are unchanged after meal ingestion, they are increased by significant weight loss, such as after bariatric surgery. In addition, adiponectin production is inhibited by a number of hormones, including testosterone, prolactin, glucocorticoids and growth hormone, and by inflammation and oxidative stress in adipose tissue. Smoking decreases, while moderate alcohol consumption increases, circulating adiponectin concentrations. Dietary fatty acid composition in rodents influences adiponectin production via ligand-activated nuclear receptors (PPARs); however, current evidence in humans is equivocal. In addition to PPAR agonists (such as thiazolidinediones and fibrates), a number of pharmacological agents (angiotensin receptor type 1 blockers, ACE inhibitors, and cannabinoid receptor antagonists) used in treatment of the metabolic syndrome also increase adiponectin concentrations in humans.

UR - http://www.scopus.com/inward/record.url?scp=44449111714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449111714&partnerID=8YFLogxK

U2 - 10.1089/met.2007.0029

DO - 10.1089/met.2007.0029

M3 - Article

C2 - 18510434

AN - SCOPUS:44449111714

VL - 6

SP - 87

EP - 102

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 2

ER -